Tarsus Pharmaceuticals, Inc. TARS Increase (Decrease) in Other Receivables

Increase (Decrease) in Other Receivables at other companies

ACM ResearchACMR

$406K+106%

State StreetSTT

$313M+26.7%

Moelis & CompanyMC

-$347K-102%

AnterixATEX

-$2.93M—

GE VernovaGEV

-$610M+33.6%

NWN

Northwest NaturalNWN

-$21.66M-39.6%

Other financials

Income statement

See full

Revenue$162.1M+107%

Gross profit$152.7M+109%

Operating income-$6.1M+76.7%

Net income-$7.0M+72.3%

EPS (diluted)-$0.16+75.0%

Balance sheet

See full

Cash & equivalents$104.2M-41.6%

Total debt$88.7M+22.5%

Total equity$349.0M+1.9%

Total assets$581.1M+16.1%

Cash flow

See full

Operating cash flow-$24.7M-19.4%

CapEx$5.8M+886%

Free cash flow-$30.5M-43.4%

Valuation

See full

Market cap$2.89B+41.1%

Profitability

See full

Operating margin-9.5%-4.2pp

Net margin-9%-4.0pp

FCF margin-28%-12.6pp

Returns & leverage

See full

Return on equity-14%-5.2pp

Debt / equity0.3×0.0×

Current ratio3.7×-1.8×

Where this comes from

Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherReceivables.

The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tarsus Pharmaceuticals, Inc.'s increase (decrease) in other receivables.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Tarsus Pharmaceuticals, Inc.'s increase (decrease) in other receivables?: Tarsus Pharmaceuticals, Inc. (TARS) reported increase (decrease) in other receivables of -$189K in Q1 2026.
How has Tarsus Pharmaceuticals, Inc.'s increase (decrease) in other receivables changed year-over-year?: Tarsus Pharmaceuticals, Inc.'s increase (decrease) in other receivables decreased by 144.1% year-over-year, from $429K to -$189K.